MYGN: Myriad Genetics, Inc. - Summary | Jitta

Myriad Genetics, Inc.

NASDAQ:MYGN

Price
$32.05
Loss Chance
52.5%
4.95JITTA SCORE
61.23%Above Jitta Line
Jitta Ranking
132 / 811
1,776 / 4,749
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (19)
Recent Business Performance (57)
Financial Strength (82)
Return to Shareholders (42)
Competitive Advantage (69)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Debt LevelLow Long Term Debt
CapExVery Low
Revenue and EarningEarning decline from 2015-2018
Operating MarginInconsistent
Recent Business PerformanceEarning decline 94.33% in the last quarter (yoy)
Key Stats
Jitta Score
Jitta Line
4.95
61.23%
1.76
0.93%
2.38
0.68%
Biotechnology
4.30
34.34%
6.35
25.01%
0.95
100.00%
COMPANY DESCRIPTION
Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents. It also provides Vectra DA, a protein quantification test for assessing the disease activity of rheumatoid arthritis; Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer; EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice HRD, a companion diagnostic to measure three modes of homologous recombination deficiency. In addition, Myriad Genetics, Inc. offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. The company has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.